报价延迟最少15分钟:2026/11/14 14:25 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
29.72 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.76/1.09
|
|
企业价值
6.10B
|
| 资产负债 |
|
每股账面净值
5.11
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
1.24B
|
|
每股收益
2.94
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. |
